Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
With the world impacted by the pandemic, the goal to bring medical alternatives to market first is now the utmost priority for many pharmaceutical companies. In support of finding these solutions, Samsung Biologics has signed a contract manufacturing agreement with GlaxoSmithKline (GSK) to produce neutralizing antibodies for COVID-19.
In April, GSK invested $250 million in the research of Vir Biotechnology to create a collaborative COVID-19 antibody treatment. With no approved treatment currently on the market, the collaborative efforts are looking at antibodies of recovered patients to see how they can help new patients recover. This is different than plasma therapy with antibodies because Vir is selecting key antibodies from the plasma to establish a process easier to administer on a large scale, making it more efficient to reach a global market. Samsung Biologics looks to help speed up that solution by offering its manufacturing service to GSK
The boost of outsourcing contracts that Samsung Biologics has gained during the COVID-19 pandemic can be largely chalked up to their unwavering drive towards quality and innovation. The company prides itself on offering a wide range of services, so clients need fewer jumps in their production and testing process.
Samsung Biologics also recently announced plans for a fourth plant expansion—estimated to invest around 2 billion USD—which will maximize operational efficiency, scale up its development and manufacturing capabilities, and through a second bio complex, foster biotech companies with an Open Innovation Center and global R&D facility.
In a time where resilient supply chains and pharmaceutical solutions are desperately needed, Samsung Biologics is filling the gap. Clients can use the large capacity and proven regulatory track record to place their products in good hands for a faster-to-market turnaround. The company also works to cut excess production time and create a development process that works best for the client. The goal is to get quality products into the hands of the patients that desperately need them.
This article does not necessarily reflect the opinions of the editors or management of EconoTimes
